Ukwelashwa kwe-UMIPIC

I-Slow Release Depot Therapy

I-Ultra Minimum Incision eyenzelwe wena uqobo I-Intra-Tumoral Chemo-Immuno Therapy

Umuthi oyinhlanganisela omelene nomdlavuza owakhiwe inhlanganisela yokwakhiwa kokukhululwa okuqhubekayo, umuthi we-chemotherapy (isidakamizwa esikabili), kanye ne-immune adjuvant ijova ngokuqondile esimila futhi ishunyekwe esimila ngaphansi kokuqondisa kwe-CT, i-ultrasound, noma i-endoscopy. Umuthi wokulwa nomdlavuza ukhishwa kancane kancane phakathi kwezinsuku ezingu-7-20, ubulala amangqamuzana omdlavuza, ugweme imiphumela emibi yesidakamizwa emzimbeni wonke futhi ufeze umgomo wokuqeda isisu; I-self tumor antigens ekhishwe amangqamuzana omdlavuza abulawa izidakamizwa ezihlanganisiwe ngasikhathi sinye, ngosizo lwama-immune adjuvant, asebenze ukuphendula kwesistimu yokuzivikela komzimba, ngaleyo ndlela abambe iqhaza ekuhlanzeni amaseli omdlavuza ophindaphindayo noma we-metastatic. Ukubulala okuhlosiwe okuqondiswe ngokomzimba okuqondisiwe kanye nokwelashwa kokunqunywa kwekhanda kungenziwa kumathumba amabi kanye nezilonda ze-metastatic ezingxenyeni ezihlukahlukene zomzimba, ezifanele izimila eziqinile zangaphambi kwesikhathi, ezimaphakathi, nesigaba sekwephuzile kuzo zonke izingxenye zomzimba. Lokhu kwelashwa kuthole ubuchwepheshe obunelungelo lobunikazi e-China, e-United States, nase-Australia. Kusukela yaqala ukusetshenziswa ngo-1998, iye yelapha iziguli ezinomdlavuza ezingaphezu kuka-80000 futhi yazuza imiphumela emihle yokwelashwa!

Umnikelo wethu omkhulu ukuthi ukwelapha okukhishwa okuqhubekayo kuhlanganisa izinzuzo ze-chemotherapy kanye ne-immunotherapy, futhi ngokokuqala ngqa, lezi zibili zihlangene futhi zasetshenziswa ekwelapheni kwe-intratumoral ngokungenelela. Ihlanganisa ukwelashwa kwendawo kanye nembulunga yonke, futhi ikhulise ukugxila kanye nesikhathi sesenzo somuthi ngokudedelwa okuqhubekayo kwezidakamizwa ngaphakathi kwesimila, esingagcini nje ngokudlala umthelela wendawo we-anticancer wezidakamizwa ze-chemotherapy, kodwa futhi icabangela indima ye-systemic immunotherapy, ngaleyo ndlela yenza ukushiyeka kwezinye izindlela zokwelapha, inikeza imibono emisha nezindlela zokwelapha umdlavuza, ikakhulukazi izimila ezimaphakathi nezithuthukile, ikakhulukazi ekunciphiseni ukubaluleka kokuphindaphinda kwesimila esibalulekile kakhulu; Ukwelashwa kwe-UMPIC kunenzuzo yokusebenzisa isimila njengomthombo we-antigen kanye nomuthi wokugomela i-autologous, ophinde uhambisane nokuthuthuka komuthi Owenziwe Umuntu. Futhi isetshenziswa emtholampilo, i-hapten ehlanganiswe nemithi ye-chemotherapy yokwelashwa okuqhubekayo komdlavuza we-pancreatic, ngenkathi idala umphumela we-distal, ingqikithi yawo ukuletha impendulo yokuzivikela komzimba, amaseli ahlobene ne-T-cell-CD4, CD8, DC, T kanye ne-NK, kanye nama-autoantibodies ahlobene ne-B-cell-cell: Ama-Antibodies kuya ku-P53, P16, I-Cmyc, I-Survic, i-HCC, i-Cmytac, i-HCC kanye namanye ama-oncogenes, kungokokuqala ngqa ukuthola ukuthi i-T kanye ne-B ihileleke ekuphenduleni kwamasosha omzimba, kanye nemisebenzi yomtholampilo yomphumela we-distal kanye nalokhu kwelashwa kwakhethelwa "Iziqondiso Zokusebenza Komtholampilo Zokwelashwa Kwe-Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (i-7th edition) eyakhiwe ngokuhlanganyela yi-Chinese Anti-Cancer Association, i-National Clinical Medical Research Centre eshicilelwe i-National Clinical Medical and Research Center for the Interrapy Medical Centre eshicilelwe ku-National Clinical Medical Center

Ijenali ye-Clinical Radiology, ivolumu 43, inombolo 19, 2024, 1636-1648.

UDkt.Baofa Yu kanye nethimba lakhe ucwaningo lwezintshisakalo ezinkulu lufakwe njengokulandelayo:

1.Izimila ezincane ezikude zingalawulwa, ngobufakazi kanye nezihloko;

2.I-subclinical focus ingalawulwa, ngakho-ke isikhathi sokuphila seziguli side;

3.Iphinde yehlise amaseli ajikelezayo wesimila (CTC) ngo-80%, isihloko okufanele sishicilelwe;

I-4.Ingakwazi ukuvuselela i-hypothalamus yobuchopho ukuba ibambe iqhaza ekuphenduleni kwamasosha omzimba, futhi ngesikhathi esifanayo, ingakwazi futhi ukugcina injabulo yobuchopho ngomculo ukuxhumanisa ukulwa nomdlavuza. I-athikili isiqediwe, futhi uprofesa we-UCSD uphakamisa ukuyihambisa emvelweni noma emithini yemvelo.

I-UMIPIC-Therapy: Ukwakhiwa kwenhlanganisela yezidakamizwa

I-Adjuvant: ukwanda kokusabela kwe-immunological kanye nokuqondile
I-ejenti esekelayo: ukubamba konke ekugxiliseni okuphezulu isikhathi eside
Ama-Antitumor agents: Imithetho egunyazwe i-FDA ibangele ukufa kwesimila ukuze kukhululwe ama-antigen ekubhimbeni.

Izinzuzo eziyisithupha ezinkulu ze-Slow Release Depot Therapy: ukukhomba okungatheni, ukunqunywa kwesimila, ukuvinjelwa kwamasosha omzimba, imigomo eminingi, ehlala isikhathi eside, iphephile futhi isebenza ngempumelelo.

Izinzuzo emaqabunga amaningi e-interception tumor
(1) I-Tumoricidal Ukungenelela endaweni eyinhloko yesimila: ngaphansi komhlahlandlela we-CT noma we-ultrasound, kuye ngosayizi wesimila, ungajova umthamo ofanelekile wesixazululo esiyingxube.
(2) Ukugcinwa kwesidakamizwa esilwa nomdlavuza: ukuhlangana kwe-oxidant ku-tumor ukubamba umuthi isikhathi eside futhi kuzuzwe ukusebenza kahle kangcono.
(3) Ukungenelela kwe-Immunological: de-bulking main tumor okwamanje ikhuthaza ukusabela kwe-immunological ukulawula isilonda esincane sesimila endaweni yesibili yesimila.
(4) Ama-antigen e-autologous isimila amaningi : ama-antigen ahlobene nesimila angumthombo we-haptenation nokugonywa: i-antigen yangempela ye-autologous, ama-antigen amaningi wangempela kanye nama-antigen enziwe umuntu ngempela.
(5) Kulula ukuyisebenzisa : Ingaphatha isimila esiyinhloko futhi ingakwazi ukwelapha isimila sesibili futhi ingadala i-immunotherapy yomuntu siqu.
(6) Iphephile futhi isebenza ngempumelelo.

I-Slow Release Depot Therapy

I-Ultra Minimum Incision eyenzelwe wena uqobo I-Intra-Tumoral Chemo-Immuno Therapy

I-UMIPIC-Therapy: Ukwakhiwa kwenhlanganisela yezidakamizwa

Sicela usishiyele umlayezo